Keyphrases
Type 2 Diabetes Mellitus (T2DM)
67%
Metformin
37%
Type 2 Diabetic Patients
30%
Placebo
27%
Finerenone
21%
Cardiovascular Outcomes
19%
Chronic Kidney Disease
17%
Randomized Placebo-controlled Trial
13%
Cardiovascular Mortality
11%
Insulin
11%
Confidence Interval
11%
Albuminuria
10%
Hazard Ratio
10%
Albumin-to-creatinine Ratio
10%
Diabetic Kidney Disease
10%
Cardiovascular Events
9%
High Risk
9%
Randomized Controlled Trial
8%
Estimated Glomerular Filtration Rate
7%
Placebo Groups
7%
Liraglutide
7%
Dapagliflozin
7%
Long-term Treatment
7%
Kidney Disease
6%
Heart Failure Hospitalization
6%
Netherlands
6%
Metformin Treatment
6%
Kidney Failure
5%
Insulin Therapy
5%
Endothelial Function
5%
Sodium-glucose Cotransporter 2 Inhibitors (SGLT2i)
5%
Advanced Type
5%
Hemoglobin A1c (HbA1c)
5%
Nonfatal Myocardial Infarction
5%
Glycemic Control
5%
Type 1 Diabetes Mellitus (T1DM)
5%
Pharmacology, Toxicology and Pharmaceutical Science
Non Insulin Dependent Diabetes Mellitus
100%
Placebo
57%
Metformin
41%
Finerenone
21%
Chronic Kidney Failure
17%
Albuminuria
13%
Randomized Controlled Trial
13%
Cardiovascular Disease
12%
Creatinine
11%
Helicobacter Infection
9%
Heart Infarction
8%
Heart Failure
8%
Diabetic Nephropathy
8%
Sodium Glucose Cotransporter 2 Inhibitor
8%
Hemoglobin A1c
7%
Statin (Protein)
7%
Adverse Event
7%
Liraglutide
7%
Dapagliflozin
7%
Randomized Clinical Trial
7%
Kidney Disease
6%
Low Density Lipoprotein Cholesterol
6%
Disease
6%
Kidney Failure
5%
Sitagliptin
5%
Metronidazole
5%
Side Effect
5%
Medicine and Dentistry
Maturity Onset Diabetes of the Young
58%
Glycon
44%
Placebo
33%
Cardiovascular System
21%
Patient with Type 2 Diabetes
21%
Post-Hoc Analysis
14%
Randomized Controlled Trial
11%
Cardiovascular Disease
10%
Hazard Ratio
8%
Chronic Kidney Disease
7%
Urinary System
7%
Sitagliptin
5%
Blood Pressure
5%
Insulin Pump
5%
Creatinine
5%
Glycemic Control
5%
Endothelial Function
5%
Systematic Review
5%
Biological Marker
5%
C-Peptide
5%
Liraglutide
5%
Diabetic Nephropathy
5%
